TY - JOUR T1 - Propranolol for infantile haemangiomas: review of report of a consensus conference JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed SP - 95 LP - 97 DO - 10.1136/archdischild-2013-305027 VL - 99 IS - 3 AU - Lauren Biesbroeck AU - Heather A Brandling-Bennett Y1 - 2014/06/01 UR - http://ep.bmj.com/content/99/3/95.abstract N2 - Infantile haemangiomas (IHs) are common benign vascular tumours of infancy, most of which do not require treatment. Complications for which treatment is indicated include impairment of vital function by ocular or airway involvement, potential to cause significant disfigurement, and ulceration. Case reports, case series and anecdotal experience since 2008 have established that propranolol is a rapidly effective and generally well-tolerated treatment for IHs in comparison with previously available therapies such as corticosteroids, vincristine and interferon.1–4 Recently published recommendations provide a provisional set of best practices meant to standardise the approach to the use of propranolol for IHs (see box 1). Box 1 Resources http://pediatrics.aappublications.org/content/131/1/128Link to full guideline In January 2013, a multispecialty group sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases published consensus recommendations entitled: ‘Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference.’5 The goal of the conference was ‘to develop a standardised, consensus-derived set of best practices for the use of propranolol in infants with infantile hemangioma.’ In all, 28 participants from five specialties (including paediatrics, dermatology, otolaryngology, cardiology, haematology/oncology) and 12 US institutions participated in the conference. These participants reviewed the available literature on propranolol use for IH and developed consensus protocols. There are no previous guidelines … ER -